Albireo Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Albireo Pharma's estimated annual revenue is currently $24.2M per year.
- Albireo Pharma's estimated revenue per employee is $193,440
- Albireo Pharma's total funding is $40M.
Employee Data
- Albireo Pharma has 125 Employees.
- Albireo Pharma grew their employee count by -22% last year.
Albireo Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Pharmaceutical Development | Reveal Email/Phone |
2 | VP, Global Commercial Analytics | Reveal Email/Phone |
3 | SVP, Global Head Medical Affairs | Reveal Email/Phone |
4 | VP Translational Science | Reveal Email/Phone |
5 | Associate General Counsel and Chief Compliance Officer | Reveal Email/Phone |
6 | VP, Manufacturing Operations | Reveal Email/Phone |
7 | SVP, Global Market Access | Reveal Email/Phone |
8 | Senior Director, Medical Science Liaison | Reveal Email/Phone |
9 | Director, Clinical Operations | Reveal Email/Phone |
10 | Reimbursement & Patient Access Director, U.S. | Reveal Email/Phone |
Albireo Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Albireo Pharma?
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo's lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo's clinical pipeline also includes two Phase 2 product candidates. Albireo's elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden. For more information on Albireo, please visit www.albireopharma.com.
keywords:N/A
$40M
Total Funding
125
Number of Employees
$24.2M
Revenue (est)
-22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Albireo Pharma News
Albireo Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid...
Given that Albireo Pharma didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business...
Last September, the FDA blessed Mirum Pharmaceuticals' Livmarli as the first treatment for Alagille syndrome. Mirum also is testing the drug in PFIC and biliary...
Post-AASLD Business Update November 16, 2021 (Nasdaq: ALBO) For Media & Investors Only ©2021 Albireo Pharma, Inc. All rights reserved Forward Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 19 ...
TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed by Singapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients in Japan, today entered into an exclusive licensing agreement with Albireo Ph ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $37.5M | 125 | -5% | $200.4M |
#2 | $7.5M | 125 | 13% | N/A |
#3 | $18.1M | 125 | 28% | $30M |
#4 | $26.3M | 125 | 4% | N/A |
#5 | $22.5M | 125 | 23% | N/A |